2025年6月15日 周日
首页 > 过刊浏览>2019年第59卷第4期 >601-611. DOI:10.13343/j.cnki.wsxb.20180220
PDF HTML阅读 XML下载 导出引用 引用提醒
黄病毒NS2B-NS3pro蛋白酶的结构研究进展
作者:
基金项目:

国家重点基础研究发展计划（973计划）（2015CB859800）


Research progress on structure of Flavivirus NS2B-NS3 protease
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [45]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    黄病毒能引起严重的人类疾病，但是并无特定药物来治疗病毒感染。黄病毒非结构蛋白NS3的N端区域及其辅因子NS2B构成蛋白酶，该酶切割病毒的多聚蛋白形成成熟的结构蛋白和非结构蛋白来帮助病毒完成增殖过程。NS2B-NS3pro蛋白酶在黄病毒生命周期中起关键的作用，使之成为抗病毒药物研发的重要靶标。本文综述了黄病毒属中寨卡病毒、登革热病毒、西尼罗病毒的NS2B-NS3pro蛋白酶结构的研究进展，并介绍了相关抑制剂与蛋白酶形成的复合物结构，以期为研发抗黄病毒药物提供必要的参考。

    Abstract:

    Flavivirus infection causes severe human disease, but no specific drugs are available to treat flavivirus infection. The N terminal region of non-structural protein 3 (NS3) of flavivirus and its cofactor NS2B constitute protease, and the polyprotein produced by virus is cleaved by protease into structural and non-structural proteins that are essential for the replication of the virus. NS2B-NS3pro represents an attractive drug target due to its critical role in the life cycle of flavivirus. Here we review the structural advances of NS2B-NS3pro of Zika Virus, Dengue Virus and West Nile Virus as well as the complex structures of some protease with inhibitors, these will provide necessary references for the future antiviral drug design.

    参考文献
    [1] Brecher M, Li Z, Liu BB, Zhang J, Koetzner CA, Alifarag A, Jones SA, Lin QS, Kramer LD, Li HM. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease. PLoS Pathogens, 2017, 13(5):e1006411.
    [2] Calvet G, Aguiar RS, Melo ASO, Sampaio SA, de Filippis I, Fabri A, Araujo ESM, de Sequeira PC, de Mendonça MCL, de Oliveira L, Tschoeke DA, Schrago CG, Thompson FL, Brasil P, dos Santos FB, Nogueira RMR, Tanuri A, de Filippis AMB. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil:a case study. The Lancet Infectious Diseases, 2016, 16(6):653-660.
    [3] Chen LH, Hamer DH. Zika virus:rapid spread in the western hemisphere. Annals of Internal Medicine, 2016, 164(9):613-615.
    [4] Possas C, Brasil P, Marzochi MC, Tanuri A, Martins RM, Marques ET, Bonaldo MC, Ferreira AG, Lourenço-de-Oliveira R, Nogueira RMR, Sequeira PC, Marzochi KB, Homma A. Zika puzzle in Brazil:peculiar conditions of viral introduction and dissemination-a review. Memórias do Instituto Oswaldo Cruz, 2017, 112(5):319-327.
    [5] Gulland A. Zika virus is a global public health emergency, declares WHO. BMJ, 2016, 352:i657.
    [6] Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae:the viruses and their replication//Knipe DM, Howley PM. Fields Virology. 5th ed. Philadelphia:Lippincott-Raven Publishers, 2007.
    [7] Lim SP, Wang QY, Noble CG, Chen YL, Dong HP, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. Ten years of dengue drug discovery:progress and prospects. Antiviral Research, 2013, 100(2):500-519.
    [8] Noble CG, Seh CC, Chao AT, Shi PY. Ligand-bound structures of the dengue virus protease reveal the active conformation. Journal of Virology, 2012, 86(1):438-446.
    [9] Verma R, Khanna P, Chawla S. Yellow fever vaccine:an effective vaccine for travelers. Human Vaccines & Immunotherapeutics, 2014, 10(1):126-128.
    [10] Yun SI, Lee YM. Japanese encephalitis:the virus and vaccines. Human Vaccines & Immunotherapeutics, 2014, 10(2):263-279.
    [11] Salam KA, Akimitsu N. Hepatitis C virus NS3 inhibitors:current and future perspectives. Biomed Research International, 2013, 2013:467869.
    [12] Zika virus outbreaks in the Americas. Weekly Epidemiological Record, 2015, 90(45):609-610.
    [13] Thomas DL, Sharp TM, Torres J, Armstrong PA, Munoz-Jordan J, Ryff KR, Martinez-Quiñones A, Arias-Berríos J, Mayshack M, Garayalde GJ, Saavedra S, Luciano CA, Valencia-Prado M, Waterman S, Rivera-García B. Local transmission of zika virus——puerto rico, November 23, 2015-January 28, 2016. MMWR Morbidity and Mortality Weekly Report, 2016, 65(6):154-158.
    [14] Meaney-Delman D, Hills SL, Williams C, Galang RR, Iyengar P, Hennenfent AK, Rabe IB, Panella A, Oduyebo T, Honein MA, Zaki S, Lindsey N, Lehman JA, Kwit N, Bertolli J, Ellington S, Igbinosa I, Minta AA, Petersen EE, Mead P, Rasmussen SA, Jamieson DJ. Zika virus infection among U.S. pregnant travelers-August 2015-February 2016. MMWR Morbidity and Mortality Weekly Report, 2016, 65(8):211-214.
    [15] Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly:tip of the iceberg? Ultrasound in Obstetrics & Gynecology, 2016, 47(1):6-7.
    [16] Miner JJ, Cao B, Govero J, Smith AM, Fernandez E, Cabrera OH, Garber C, Noll M, Klein RS, Noguchi KK, Mysorekar IU, Diamond MS. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell, 2016, 165(5):1081-1091.
    [17] Lei J, Hansen G, Nitsche C, Klein CD, Zhang LL, Hilgenfeld R. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science, 2016, 353(6298):503-505.
    [18] Chen X, Yang KL, Wu C, Chen C, Hu C, Buzovetsky O, Wang ZF, Ji XY, Xiong Y, Yang HT. Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease. Cell Research, 2016, 26(11):1260-1263.
    [19] Phoo WW, Li Y, Zhang ZZ, Lee MY, Loh YR, Tan YB, Ng EY, Lescar J, Kang CB, Luo DH. Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Nature Communications, 2016, 7:13410.
    [20] Zhang ZZ, Li Y, Loh YR, Phoo WW, Hung AW, Kang CB, Luo DH. Crystal structure of unlinked NS2B-NS3 protease from Zika virus. Science, 2016, 354(6319):1597-1600.
    [21] Li Y, Zhang ZZ, Phoo WW, Loh YR, Wang WL, Liu S, Chen MW, Hung AW, Keller TH, Luo DH, Kang CB. Structural dynamics of zika virus NS2B-NS3 protease binding to dipeptide inhibitors. Structure, 2017, 25(8):1242-1250.
    [22] Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity. Journal of General Virology, 2008, 89:1010-1014.
    [23] Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S, Katzenmeier G. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. Journal of Virology, 2004, 78(24):13708-13716.
    [24] Luo DH, Vasudevan SG, Lescar J. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antiviral Research, 2015, 118:148-158.
    [25] Nitsche C, Holloway S, Schirmeister T, Klein CD. Biochemistry and medicinal chemistry of the dengue virus protease. Chemical Reviews, 2014, 114(22):11348-11381.
    [26] Collins MH, Metz SW. Progress and works in progress:update on flavivirus vaccine development. Clinical Therapeutics, 2017, 39(8):1519-1536.
    [27] Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, Hay SI, Bedi N, Bensenor IM, Castañeda-Orjuela CA, Chuang TW, Gibney KB, Memish ZA, Rafay A, Ukwaja KN, Yonemoto N, Murray CJL. The global burden of dengue:an analysis from the global burden of disease study 2013. The Lancet Infectious Diseases, 2016, 16(6):712-723.
    [28] Duyen HTL, Cerny D, Trung DT, Pang J, Velumani S, Toh YX, Qui PT, van Hao N, Simmons C, Haniffa M, Wills B, Fink K. Skin dendritic cell and Tn KWK, Shang LQ, Vasudevan SG, Yin Z. Structure-guided discovery of a novel non-peptide inhibitor of dengue virus NS2B-NS3 protease. Chemical Biology & Drug Design, 2015, 86(3):255-264.
    [46] Lee H, Ren JH, Nocadello S, Rice AJ, Ojeda I, Light S, Minasov G, Vargas J, Nagarathnam D, Anderson WF, Johnson ME. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Research, 2017, 139:49-58.
    [47] Rut W, Zhang LL, Kasperkiewicz P, Poreba M, Hilgenfeld R, Drąg M. Extended substrate specificity and first potent irreversible inhibitor/activity-based probe design for Zika virus NS2B-NS3 protease. Antiviral Research, 2017, 139:88-94.
    [48] Yin Z, Patel SJ, Wang WL, Wang G, Chan WL, Rao KRR, Alam J, Jeyaraj DA, Ngew X, Patel V, Beer D, Lim SP, Vasudevan SG, Keller TH. Peptide inhibitors of dengue virus NS3 protease. Part 1:warhead. Bioorganic & Medicinal Chemistry Letters, 2006, 16(1):36-39.
    [49] Kang CB, Keller TH, Luo DH. Zika virus protease:an antiviral drug target. Trends in Microbiology, 2017, 25(10):797-808. Dengue virus and its inhibitors:a brief review. Chemical & Pharmaceutical Bulletin, 2018, 66(3):191-206.
    [33] Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nature Structural & Molecular Biology, 2006, 13(4):372-373.
    [34] Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, Kuhn P. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. Journal of Virology, 2010, 84(6):3059-3067.
    [35] Li J, Lim SP, Beer D, Patel V, Wen DY, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP, Harris JL, Vasudevan SG. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. Journal of Biological Chemistry, 2005, 280(31):28766-28774.
    [36] Acharya D, Bai F. An overview of current approaches toward the treatment and prevention of west nile virus infection//Colpitts TM. West Nile Virus:Methods and Protocols. New York, NY:Humana Press, 2016:249-291.
    [37] Aleshin AE, Shiryaev SA, Strongin AY, Liddington RC. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Science, 2007, 16(5):795-806.
    [38] Robin G, Chappell K, Stoermer MJ, Hu SH, Young PR, Fairlie DP, Martin JL. Structure of West Nile virus NS3 protease:ligand stabilization of the catalytic conformation. Journal of Molecular Biology, 2009, 385(5):1568-1577.
    [39] Matusan AE, Kelley PG, Pryor MJ, Whisstock JC, Davidson AD, Wright PJ. Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus. Journal of General Virology, 2001, 82:1647-1656.
    [40] Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Science, 1995, 4(3):337-360.
    [41] Schöne T, Grimm LL, Sakai N, Zhang LL, Hilgenfeld R, Peters T. STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease. Antiviral Research, 2017, 146:174-183.
    [42] Poulsen A, Kang CB, Keller TH. Drug design for flavivirus proteases:what are we missing? Current Pharmaceutical Design, 2014, 20(21):3422-3427.
    [43] Steuer C, Gege C, Fischl W, Heinonen KH, Bartenschlager R, Klein CD. Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. Bioorganic & Medicinal Chemistry, 2011, 19(13):4067-4074.
    [44] Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu BB, Huang RL, Koetzner CA, Allen CA, Jones SA, Chen HY, Zhang NN, Tian M, Gao FS, Lin QS, Banavali N, Zhou J, Boles N, Xia MH, Kramer LD, Qin CF, Li HM. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Research, 2017, 27(8):1046-1064.
    [45] Li LF, Basavannacharya C, Cha
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

武晨,杨海涛,王泽方. 黄病毒NS2B-NS3pro蛋白酶的结构研究进展[J]. 微生物学报, 2019, 59(4): 601-611

复制
分享
文章指标
  • 点击次数:1217
  • 下载次数: 1630
  • HTML阅读次数: 2047
  • 引用次数: 0
历史
  • 收稿日期:2018-05-13
  • 最后修改日期:2018-10-08
  • 在线发布日期: 2019-04-03
文章二维码

科微学术

微生物学报

您是本站第 6094256 访问者

通信地址：北京市朝阳区北辰西路1号院3号 中国科学院微生物研究所   邮编：100101

电话：010-64807516    E-mail：actamicro@im.ac.cn

版权所有：微生物学报 ® 2025 版权所有